Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Veloxis Pharmaceuticals announces financial results for the first nine months of 2012

HORSHOLM, Denmark, Nov. 14, 2012 /PRNewswire/ --

Highlights:

  • Veloxis has in October 2012 entered into an exclusive distribution agreement with Chiesi Farmaceutici S.p.A, a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, for the commercialization and distribution of its novel formulation immunosuppressant drug candidate LCP-Tacro in certain countries, including Europe, Turkey and CIS countries (Russia and former USSR republics). Under the terms of the agreement, Veloxis will receive up-front and milestone payments of up to USD 47.5 million (in aggregate). The milestone payments are subject to the achievement of certain regulatory milestones and sales targets.
  • Fully subscribed offering of 1,206,779,946 new shares at DKK 0.35 per share yielding approximately DKK 405 million in net proceeds.
  • Veloxis reported an operating loss before restructuring costs of DKK 195.5 million for the first nine months of 2012 compared to a loss of DKK 196.7 million for the same period in 2011.
  • For the first nine months of 2012, Veloxis' research and development costs amounted to DKK 168.8 million compared to DKK 160.3 million during the same period in 2011.
  • On 30 September, 2012, Veloxis had cash and cash equivalents of DKK 86.7 million. The fully subscribed offering will increase the cash position with approximately DKK 405 million.

Outlook for 2012

Veloxis maintains its 2012 outlook with an operating and net loss of DKK 240-270 million for the financial year 2012.

As at 30 September 2012, the Company's cash position equaled DKK 87 million, and as at 31 December 2012, the Company's cash position is expected to be in the range of DKK 490-530 million, including the proceeds from the completed offering.

Conference call

A conference call will be held tomorrow, 15 November, 2012 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York),

To access the live conference call, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
Access code 64372811

Following the conference call, a recording will be available on the company's website http://www.veloxis.com.

Research & development update

LCP-Tacro™ in kidney transplant patients

Veloxis has completed one Phase III study and has commenced a second Phase III study of LCP-Tacro™ in kidney transplant recipients as the basis for its development programme for LCP-Tacro™ as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation. The first of these studies, the 3001 Study was a non-inferiority study performed in 326 stable kidney transplant recipients, and was successfully completed in 2011, meeting its primary efficacy and safety endpoints when compared to Prograf® (tacrolimus, Astellas Pharma Inc.). The second study, Study 3002 is being undertaken in de novo kidney transplant recipients. This study is a randomized, double-blind, multicenter study that compares once-daily LCP-Tacro™ against twice-daily Prograf® in de novo adult kidney transplant patients. The primary endpoint of the study, a composite endpoint (biopsy proven acute rejection, graft failure, loss to follow up or death), will be evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro™ compared to Prograf®. Secondary endpoints will include safety, tolerability and renal function assessments. The study completed enrollment in March 2012 of 543 patients at approximately 90 transplant centers, primarily in the U.S and Europe. Results from this study are expected mid-2013. Patients will participate in a 12-month extension period on treatment for follow-up safety assessments.

In addition to the pivotal Phase III studies, Veloxis is planning a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by LCP-Tacro's unique PK profile. The first study initiated is the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of LCP-Tacro™ in kidney transplant recipients experiencing drug-induced tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily LCP-Tacro™ tablets leads to a measurable improvement in tremor.

LCP-Tacro™ Regulatory Strategy

The U.S. submission for LCP-Tacro™, for the prophylaxis of organ rejection, to the FDA (Food and Drug Administration) is planned for the second half of 2013.  The MAA (Marketing Authorization Application) filing for LCP-Tacro™ for the prophylaxis of organ rejection with the EMA (European Medicines Agency) is projected to take place in 2013. The exact timing of this filing will be determined based on discussions with the EMA rapporteur regarding the optimal timing for regulatory submission, including consideration of timing the MAA submission relative to the availability of the 3002 de novo study data.

 

 

Financial Highlights















YTD

YTD

Q3

Q3

Year



2012

2011

2012

2011

2011



DKK'000

DKK'000

DKK'000

DKK'000

DKK'000








Income Statement






Revenue

-

-

-

-

-

Research and development costs

(168,849)

(160,291)

(49,362)

(43,079)

(222,053)

Administrative expenses

(26,654)

(36,429)

(6,961)

(12,568)

(47,814)

Operating loss before restructuring cost

(195,503)

(196,720)

(56,323)

(55,647)

(269,867)

Restructuring cost

(21,462)

-

-

-

-

Operating loss

(216,965)

(196,720)

(56,323)

(55,647)

(269,867)

Net financial income / (expenses)

1,452

11,521

993

11,363

16,048

Loss before tax

(215,513)

(185,199)

(55,330)

(44,284)

(253,819)

Tax for the period

(671)

820

(223)

1,120

1,193

Net loss for the period

(216,184)

(184,379)

(55,553)

(43,164)

(252,626)








Balance Sheet






Cash and cash equivalents

86,683

348,252

86,683

348,252

297,727

Total assets

99,590

370,865

99,590

370,865

320,927

Share capital

45,254

452,543

45,254

452,543

452,543

Total equity

42,103

322,516

42,103

322,516

255,900

Investment in property, plant and equipment

217

1,858

0

602

2,981








Cash Flow Statement






Cash flow from operating activities

(205,472)

(182,498)

(62,707)

(60,481)

(234,637)

Cash flow from investing activities

113,093

(195,879)

59,486

25,878

(169,778)

Cash flow from financing activities

(5,844)

(4,277)

(3,450)

(1,445)

(5,948)

Cash and cash equivalents at period end

86,683

348,252

86,683

348,252

297,727








Financial Ratios






Basic and diluted EPS

(0.48)

(0.41)

(0.12)

(0.10)

(0.56)

Weighted average number of shares

452,542,480

452,542,480

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

53

52

49

51

52

Assets/equity

2.37

1.15

2.37

1.15

1.25

 

The interim report is unaudited.


Revenue

For the first nine months of 2012 Veloxis had no revenue as in the same period of 2011.

Research and development costs

For the first nine months of 2012, Veloxis' research and development costs amounted to DKK 168.8 million compared to DKK 160.3 million during the same period in 2011. Research and development costs are attributable to the ongoing phase III trial in LCP-Tacro™ (de novo patients, Study 3002).

Administrative expenses

For the first nine months of 2012, Veloxis' administrative cost amounted to DKK 26.7 million compared to DKK 36.4 million during the same period in 2011.

Restructuring cost

Restructuring cost includes salary payments to former employees in connection with the reduction in headcount effected in May 2012 and a write-down of laboratory equipment and laboratory improvements due to the discontinuation of pipeline activities not related to LCP-Tacro™.

Compensation costs

For the first nine months of 2012, a total of DKK 4.4 million was recognized as share-based compensation. The cost is included in R&D and G&A. The comparable cost for 2011 was DKK 8.7 million.

In the third quarter of 2012, a total of 1,957,654 warrants have been cancelled and a total of 1,649,280 warrants have expired.

As of 30 September, 2012, there were a total of 24,031,296 warrants outstanding at an average strike price of DKK 2.8. Members of the Board of Directors held 474,735 warrants at an average strike price of DKK 6.0. Members of the Executive Management held 8,914,466 warrants at an average strike price of DKK 1.6, while other current and former employees held 14,642,095 warrants at an average strike price of DKK 3.4.

Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.

Operating loss

Veloxis' operating loss for the first nine months of 2012 was DKK 217.0 million compared to DKK 196.7 million in the corresponding period of 2011.

Financial income

During the first nine months of 2012, the Company recognized net financial income of DKK 1.5 million compared to net financial income of DKK 11.5 million in the corresponding period of 2011. The gain is mainly attributable to interest income and gains on investment bonds.

Net loss

Veloxis' net loss for the first nine months of 2012 was DKK 216.2 million compared to DKK 184.4 million in the corresponding period of 2011.

Cash flow

As at 30 September, 2012, the balance sheet reflects cash and cash equivalents of DKK 86.7 million compared to DKK 297.7 million as at 31 December, 2011. This represents a decrease of DKK 211.0 million primarily reflecting the Company's operating activities for the period.

Balance sheet

As per 30 September, 2012, total assets were DKK 99.6 million compared to DKK 320.9 million at the end of 2011.

Shareholders' equity equalled DKK 42.1 million as of 30 September, 2012, compared to DKK 255.9 million at the end of 2011.


Financial review

Veloxis reports its financial statements in Danish Kroner (DKK), which is the functional currency of the Company and the group. Solely for the convenience of the reader, this Interim Report contains a conversion of certain DKK amounts into Euro (EUR) at a specified rate. These converted amounts should not be construed as representations that the DKK amounts actually represent such EUR amounts or could be converted into EUR at the rate indicated or at any other rate. Unless otherwise indicated, conversion herein of financial information into EUR has been made using the Danish Central Bank's spot rate on 30 September, 2012, which was EUR 1.00 = DKK 7.4555.

For more information, please contact:

John D. Weinberg 

Johnny Stilou

EVP, Chief Commercial Officer         

EVP, Chief Financial Officer

Mobile: +1 908 302 3389    

Mobile: +45 21 227 227

Email: jdw@veloxis.com  

Email: jst@veloxis.com  


The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.


About LCP‐Tacro™ and tacrolimus

Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after transplantation. LCP-Tacro is an investigational drug that is being developed as a once-daily tablet version of tacrolimus with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit http://www.veloxis.com.


Executive Management's and the Board of Directors' Statement on the Interim Report


The Executive Management and the Board of Directors have considered and adopted the Interim Report of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.


Horsholm, 14 November, 2012

Executive Management


Dr. William J. Polvino

Johnny Stilou 

President & CEO 

Executive Vice President & CFO



Board of Directors


Kim Bjornstrup 

Thomas Dyrberg  

Kurt Anker Nielsen

(Chairman)  

(Deputy Chairman)



Anders Gotzsche

Mette Kirstine Agger 

Ed Penhoet

  

 


Financial Highlights









Quarterly Numbers in DKK





















Q3

Q2

Q1


Q4

Q3

Q2

Q1



2012

2012

2012


2011

2011

2011

2011



DKK'000

DKK'000

DKK'000


DKK'000

DKK'000

DKK'000

DKK'000











Income Statement









Revenue

-

-

-


-

-

-

-

Research and development costs

(49,362)

(56,639)

(62,848)


(61,763)

(43,079)

(64,951)

(52,261)

Administrative expenses

(6,961)

(9,462)

(10,231)


(11,385)

(12,568)

(12,137)

(11,724)

Operating loss before restructuring cost

(56,323)

(66,101)

(73,079)


(73,148)

(55,647)

(77,088)

(63,985)

Restructuring cost

-

(21,462)

-


-

-

-

-

Operating loss

(56,323)

(87,563)

(73,079)


(73,148)

(55,647)

(77,088)

(63,985)

Net financial income / (expenses)

993

2,051

(1,592)


4,528

11,363

2,008

(1,850)

Loss before tax

(55,330)

(85,512)

(74,671)


(68,620)

(44,284)

(75,080)

(65,835)

Tax for the period

(223)

(130)

(318)


373

1,120

(300)

-

Net loss for the period

(55,553)

(85,642)

(74,989)


(68,247)

(43,164)

(75,380)

(65,835)











Balance Sheet









Cash and cash equivalents

86,683

152,720

213,786


297,727

348,252

402,213

462,319

Total assets

99,590

167,799

235,187


320,927

370,865

426,860

490,578

Share capital

45,254

45,254

452,543


452,543

452,543

452,543

452,543

Total equity

42,103

98,968

182,545


255,900

322,516

363,606

436,200

Investment in property, plant and equipment

0

126

91


1,123

602

635

621











Cash Flow Statement









Cash flow from operating activities

(62,707)

(62,400)

(80,364)


(52,139)

(60,481)

(56,621)

(65,396)

Cash flow from investing activities

59,486

24,174

29,433


26,101

25,878

77,845

(299,602)

Cash flow from financing activities

(3,450)

(1,085)

(1,310)


(1,670)

(1,445)

(1,426)

(1,407)

Cash and cash equivalents at period end

86,683

152,720

213,786


297,727

348,252

402,213

462,319











Financial Ratios









Basic and diluted EPS

(0.12)

(0.19)

(0.17)


(0.15)

(0.10)

(0.17)

(0.15)

Weighted average number of shares

452,542,480

452,542,480

452,542,480


452,542,480

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

49

55

55


51

51

52

54

Assets/equity

2.37

1.70

1.29


1.25

1.15

1.17

1.12


Financial Highlights









Quarterly Numbers in EUR





















Q3

Q2

Q1


Q4

Q3

Q2

Q1



2012

2012

2012


2011

2011

2011

2011



EUR'000

EUR'000

EUR'000


EUR'000

EUR'000

EUR'000

EUR'000











Income Statement









Revenue

-

-

-


-

-

-

-

Research and development costs

(6,621)

(7,597)

(8,430)


(8,284)

(5,778)

(8,712)

(7,010)

Administrative expenses

(934)

(1,269)

(1,372)


(1,527)

(1,686)

(1,628)

(1,572)

Operating loss before restructuring cost

(7,555)

(8,866)

(9,802)


(9,811)

(7,464)

(10,340)

(8,582)

Restructuring cost

-

(2,879)

-


-

-

-

-

Operating loss

(7,555)

(11,745)

(9,802)


(9,811)

(7,464)

(10,340)

(8,582)

Net financial income / (expenses)

134

275

(214)


607

1,524

269

(248)

Loss before tax

(7,421)

(11,470)

(10,016)


(9,204)

(5,940)

(10,071)

(8,830)

Tax for the period

(30)

(17)

(42)


50

150

(40)

-

Net loss for the period

(7,451)

(11,487)

(10,058)


(9,154)

(5,790)

(10,111)

(8,830)











Balance Sheet









Cash and cash equivalents

11,627

20,484

28,675


39,934

46,711

53,948

62,010

Total assets

13,358

22,507

31,545


43,046

49,744

57,254

65,801

Share capital

6,070

6,070

60,699


60,699

60,699

60,699

60,699

Total equity

5,647

13,274

24,485


34,324

43,259

48,770

58,507

Investment in property, plant and equipment

0

17

12


151

81

85

83











Cash Flow Statement









Cash flow from operating activities

(8,411)

(8,370)

(10,779)


(6,993)

(8,112)

(7,595)

(8,772)

Cash flow from investing activities

7,979

3,242

3,948


3,501

3,471

10,441

(40,185)

Cash flow from financing activities

(463)

(146)

(176)


(224)

(194)

(191)

(189)

Cash and cash equivalents at period end

11,627

20,484

28,675


39,934

46,711

53,948

62,010











Financial Ratios









Basic and diluted EPS

(0.02)

(0.03)

(0.02)


(0.02)

(0.01)

(0.02)

(0.02)

Weighted average number of shares

452,542,480

452,542,480

452,542,480


452,542,480

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

49

55

55


51

51

52

54

Assets/equity

2.37

1.70

1.29


1.25

1.15

1.17

1.12


 

Income statement and statement of comprehensive income

Income Statement

Consolidated








(DKK'000)

YTD

YTD

Q3

Q3

Year



2012

2011

2012

2011

2011








Revenue

-

-

-

-

-

Research and development costs

(168,849)

(160,291)

(49,362)

(43,079)

(222,053)

Administrative expenses

(26,654)

(36,429)

(6,961)

(12,568)

(47,814)








Operating loss before restructuring cost

(195,503)

(196,720)

(56,323)

(55,647)

(269,867)








Restructuring cost

(21,462)

-

-

-

-








Operating loss

(216,965)

(196,720)

(56,323)

(55,647)

(269,867)








Financial income

6,907

22,746

1,681

12,493

33,238

Financial expenses

(5,455)

(11,225)

(688)

(1,130)

(17,190)








Loss before tax

(215,513)

(185,199)

(55,330)

(44,284)

(253,819)








Tax for the period

(671)

820

(223)

1,120

1,193








Net loss for the period

(216,184)

(184,379)

(55,553)

(43,164)

(252,626)





























Basic and diluted EPS

(0.48)

(0.41)

(0.12)

(0.10)

(0.56)








Weighted average number of shares

452,542,480

452,542,480

452,542,480

452,542,480

452,542,480





























Statements of comprehensive income

Consolidated








(DKK'000)

YTD

YTD

Q3

Q3

Year



2012

2011

2012

2011

2011








Net loss for the period

(216,184)

(184,379)

(55,553)

(43,164)

(252,626)

  Other comprehensive income:






  Currency translation differences

361

(31)

113

(338)

(163)








  Other comprehensive income for the period

361

(31)

113

(338)

(163)








Total comprehensive income for the period

(215,823)

(184,410)

(55,440)

(43,502)

(252,789)


Balance sheet

 

Assets




Consolidated











(DKK'000)


30 Sept.


30 Sept.


31 Dec.




2012


2011


2011









Patent rights and software


2,347


2,111


2,563









Intangible assets


2,347


2,111


2,563









Property, plant and equipment


3,958


9,356


8,967

Leasehold improvements


156


4,414


3,880









Property, plant and equipment


4,114


13,770


12,847









Non-current assets


6,461


15,881


15,410









Other receivables


5,224


5,270


5,480

Prepayments


1,222


1,462


2,310









Receivables


6,446


6,732


7,790









Investment bonds


53,487


195,459


166,797

Cash


33,196


152,793


130,930









Cash and cash equivalents


86,683


348,252


297,727









Current assets


93,129


354,984


305,517









Assets


99,590


370,865


320,927


Balance sheet

 

Equity & Liabilities




Consolidated











(DKK'000)


30 Sept.


30 Sept.


31 Dec.




2012


2011


2011









Share capital


45,254


452,543


452,543

Special reserve


407,289


-


-

Translation reserves


2,292


2,063


1,931

Retained earnings/loss


(412,732)


(132,090)


(198,574)









Equity


42,103


322,516


255,900









Finance lease


722


4,831


3,715









Non-current liabilities


722


4,831


3,715









Finance lease


4,109


5,166


4,612

Trade payables


25,078


16,153


28,263

Other payables


27,578


22,199


28,437









Current liabilities


56,765


43,518


61,312









Liabilities


57,487


48,349


65,027









Equity and liabilities


99,590


370,865


320,927


Cash flow statements

 

Cash Flow Statement

Consolidated








(DKK'000)

YTD

YTD

Q3

Q3

Year



2012

2011

2012

2011

2011








Operating loss

(216,965)

(196,720)

(56,323)

(55,647)

(269,867)








Share-based payment

4,375

8,688

924

2,412

10,451

Depreciation and amortization

9,168

5,713

440

1,920

7,320

Changes in working capital

(2,151)

(3,638)

(7,694)

(11,060)

13,094








Cash flow from operating activities before interest

(205,573)

(185,957)

(62,653)

(62,375)

(239,002)








Interest received

1,234

4,307

272

963

5,418

Interest paid

(462)

(1,668)

(103)

(189)

(2,246)

Corporate tax paid

(671)

820

(223)

1,120

1,193








Cash flow from operating activities

(205,472)

(182,498)

(62,707)

(60,481)

(234,637)















Purchase of property, plant and equipment

(217)

(1,858)

(0)

(602)

(2,981)

Investments in bonds

(16,804)

(386,033)

(4,869)

(8,365)

(406,128)

Sale of bonds

130,114

190,574

64,355

34,845

239,331

Cash transfer to restricted security deposit

-

1,438

-

-

-








Cash flow from investing activities

113,093

(195,879)

59,486

25,878

(169,778)















Installments on bank borrowings and finance lease

(3,495)

(4,277)

(1,101)

(1,445)

(5,948)

Costs related to capital increases

(2,349)

-

(2,349)

-

-








Cash flow from financing activities

(5,844)

(4,277)

(3,450)

(1,445)

(5,948)















Increase/(decrease) in cash

(98,223)

(382,654)

(6,671)

(36,048)

(410,363)

Cash at beginning of period

130,930

530,081

39,747

180,274

531,519

Exchange gains/(losses) on cash

489

5,366

120

8,567

9,774








Cash at end of period

33,196

152,793

33,196

152,793

130,930















Cash and cash equivalents at end of period comprise:













Investment bonds

53,487

195,459

53,487

195,459

166,797

Deposit on demand and cash

33,196

152,793

33,196

152,793

130,930










86,683

348,252

86,683

348,252

297,727


Statement of changes in equity

 

Consolidated Equity











Number of Shares


Share Capital

Share Premium

Special Reserves

Translation Reserves

Retained Earnings

Total





DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000











Equity as of 1 January 2011

452,542,480


452,543

43,601

-

2,094

-

498,238











Total comprehensive income






(31)

(184,379)

(184,410)











Share-based payment







8,688

8,688

Transfer of retained earnings




(43,601)



43,601

-











Equity as of 30 September 2011

452,542,480


452,543

-

-

2,063

(132,090)

322,516











Total comprehensive income






(132)

(68,247)

(68,379)











Share-based payment







1,763

1,763











Equity as of 31 December 2011

452,542,480


452,543

-

-

1,931

(198,574)

255,900











Total comprehensive income






361

(216,184)

(215,823)











Reduction of share capital



(407,289)


407,289



-

Share-based payment







4,375

4,375

Costs related to capital increases




(2,349)




(2,349)

Transfer of retained earnings




2,349



(2,349)

-











Equity as of 30 September 2012

452,542,480


45,254

-

407,289

2,292

(412,732)

42,103


 


Notes

1.         Accounting policies

The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2011.

The income statement presents expenses by function and a new subtotal "Operating loss before restructuring costs" which exclude restructuring costs. This subtotal is considered relevant in understanding the financial performance and outlook for 2012 of the group.

 

2.         Accounting estimates

Impairment tests

In accordance with IAS 36, property, plant and equipment are tested for impairment if there are indications of impairment. Due to the restructuring of the organisation announced on 23 May 2012 Management has performed an impairment test of the book value of property, plant and equipment primarily consisting of leasehold improvements and laboratory equipment.  According to Veloxis' accounting policies regarding impairment tests a write-down is made to the highest value of an estimated sales price or calculated net present value. Leasehold improvements and certain laboratory equipment will no longer be deployed by Veloxis due to the restructuring. It has been assessed that the value in use and the estimated sales price amount to DKK 0 million. The book value of laboratory equipment still being used by Veloxis as part of the LCP-Tacro Phase III study is considered by management not to be impaired.

On basis of the impairment test a write-down was made on 30 June 2012 of DKK 6.1 million. At 30 September 2012 write-down for the period 1 January to 30 September 2012 amounts to DKK 6.1 million (30 September 2011: DKK 0 million).

 

SOURCE Veloxis Pharmaceuticals

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
In this report Enterprise Management Associates (EMA) analysts explore the ways in which gaining visibility and control over high-privilege access helps organizations achieve regulatory compliance, assure responsible governance, and improve security all while reducing IT operational co...
Maintaining lower development environments can become an unbearable headache. Changes to an application, service or API are seldom completely testable, leaving us to discover broken code when it’s too late. This lack of visibility into application dependencies severely limits early cod...
More and more enterprises today are doing business by opening up their data and applications through APIs. Though forward-thinking and strategic, exposing APIs also increases the surface area for potential attack by hackers. To benefit from APIs while staying secure, enterprises and se...
SYS-CON Events announced today that ActiveState, providers of Stackato, the platform for the agile enterprise, has been named “Silver Sponsor” of SYS-CON's 2nd DevOps Summit, which will take place on June 10–12, 2014, at the Javits Center in New York City, New York. ActiveState believ...
Many cloud hosting providers have achieved ticket-of-entry credibility in the data warehousing industry by building simple colocation centers. A first-tier database as a service (DBaaS) contender, however, is set apart by a value-added service approach that is strategic, consultative a...
VASCO Data Security International, Inc., has announced on Tuesday that it will release its Q1 2014 results on Thursday, April 24th. On April 24, at 10.00 am EDT/16.00 CET, VASCO will hold a conference call, which will be streamed on the VASCO website. Mr. T. Kendall Hunt, Chairman an...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE